HC Wainwright Reiterates Buy Rating for Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals (NASDAQ:PHIO)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $14.00 price objective on the stock.

Phio Pharmaceuticals Stock Up 1.8%

PHIO opened at $2.21 on Wednesday. Phio Pharmaceuticals has a 52 week low of $0.97 and a 52 week high of $9.79. The business has a fifty day simple moving average of $2.13 and a 200-day simple moving average of $1.98. The firm has a market cap of $10.61 million, a P/E ratio of -0.20 and a beta of 0.84.

Hedge Funds Weigh In On Phio Pharmaceuticals

An institutional investor recently bought a new position in Phio Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned 0.59% of Phio Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.